TP53 and acute myeloid leukemia: Gene mutations seen in t-AML and s-AML include activating mutations in tyrosine kinase RAS/BRAF pathways leading to an increase in cell proliferation, inactivating mutations in genes encoding hematopoietic transcription factors resulting in disrupted cell differentiation, and inactivating mutations in the tumor suppressor gene TP53.